Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Exclusion Criteria

• •1. Non-idiopathic PD (atypical parkinsonism, secondary \[acquired or symptomatic\] parkinsonism, Parkinson-plus syndrome).
• •2. Dyskinesia disability score \>3 in the Unified Parkinson's Disease Rating Scale UPDRS) Sub-section IV A, item 33.
• •3. Severe and/or unpredictable OFF periods.
• •4. Treatment with prohibited medication: entacapone, tolcapone, neuroleptics, venlafaxine, MAO inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1mg/day), or antiemetics with antidopaminergic action (except domperidone) within the month before screening.
• •5. Treatment with apomorphine within the month before screening or likely to be needed at any time during the study.
• •6. Dosage change of concomitant anti-PD medication within 4 weeks of screening.
• •7. Previous or planned (during the entire study duration, including the OL period)deep brain stimulation.
• •8. Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned stereotactic surgery during the study period.
• •9. Any investigational medicinal product within the 3 months (or within 5 half-lives, whichever is longer) before screening.
• •10. Any medical condition that might place the subject at increased risk or interfere with assessments.